Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures - A case report

Acta Orthopaedica

Volumn 82, Issue 3, 2011, Pages 380-382

  Puah, Ken Lee ^a   Tan, Mann Hong ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

ADULT; BONE DENSITY; CASE REPORT; CHINESE; FEMALE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FOLLOW UP; FRACTURE HEALING; HEMATOMA; HUMAN; LEG PAIN; NOTE; PLATE FIXATION; RADIOGRAPHY; STRESS FRACTURE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE PLATES; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURE HEALING; FRACTURES, STRESS; HUMANS; MIDDLE AGED;

EID: 79957833420     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2011.581267     Document Type: Note

References (9)

1. Black D M, Schwartz A V, Ensrud K E, Cauley J A, Levis S, Quandt S A, Sat-terfeld S, Wallace R B, Bauer D C, Palermo L, Wehren L E, Lombardi A, Santora A C and Cummings S R. Effects of continuing or stopping alendro-nate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296 (24): 2927-38. (Pubitemid 46021497)
2. Burr D B, Forwood M R, Fyhrie D P, Martin R B, Schaffer M B, Turner C H. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997; 12 (1): 6-15. (Pubitemid 27053606)
3. Heino T J, Kurata K, Higaki H, Väänänen H K. Evidence for the role of osteo-cytes in the initiation of targeted remodeling. Technol Health Care 2009; 17 (1): 49-56.
4. Khan S A, Kanis J A, Vasikaran S, Kline W F, Matuszewski B K, McClo-skey E V, Beneton M N, Gertz B J, Sciberras D G, Holland S D, Orgee J, Coombes G M, Rogers S R, Porras A G. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12 (10): 1700-7. (Pubitemid 27422371)
5. Kwek E B, Goh S K, Koh J S, Png M A, Howe T S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008; 39 (2): 224-31. Epub 2008 Jan 28.
6. Lenart B A, Neviaser A S, Lyman S, Chang C C, Edobor-Osula F, Steele B, van der Meulen M C, Lorich D G, Lane J M. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20 (8): 1353-62. Epub 2008 Dec 9.
7. Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524-31. (Pubitemid 32416465)
8. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80 (4): 413-5.
9. Tan S C, Koh S B, Goh S K, Howe T S. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2010; 14. [Epub ahead of print]